The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

NCT04977479 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

Systemic Allergic Reaction

Interventions

BIOLOGICAL: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
OTHER: Placebo
BIOLOGICAL: Pfizer-BioNTech COVID-19 Vaccine, Bivalent

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)